Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study by Jermann, M
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2004
Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or
transformed B-cell lymphomas: results of a phase II study
Jermann, M
Abstract: Background: Relapsed or refractory diffuse large B-cell and mantle-cell lymphoma have a
poor prognosis. The EPOCH regimen and rituximab monotherapy have demonstrated activity as salvage
therapies. Because of their non-overlapping toxicity, we evaluated their combination as salvage therapy in
a phase II study. Patients and methods: Patients with relapsed or refractory CD20-positive large B-cell
and mantle-cell lymphoma were offered treatment with rituximab 375 mg/m2 intravenously (i.v.) on day
1, doxorubicin 15 mg/m2 as a continuous i.v. infusion on days 2-4, etoposide 65 mg/m2 as a continuous
i.v. infusion on days 2-4, vincristine 0.5 mg as a continuous i.v. infusion on days 2-4, cyclophosphamide
750 mg/m2 i.v. on day 5 and prednisone 60 mg/m2 orally on days 1-14. Results: Fifty patients, with
a median age of 56 years (range 23-72), entered the study. Twenty-five had primary diffuse large B-cell
lymphoma, 18 transformed large B-cell lymphoma and seven mantle-cell lymphoma. The median number
of prior chemotherapy regimens was 1.7 (range one to four). The median number of treatment cycles was
four (range one to six). Possible treatment-related death occurred in two patients. Objective responses
were obtained in 68% of patients (28% complete responses, 40% partial responses). Nineteen patients
received consolidating high-dose chemotherapy with autologous stem-cell transplantation. The median
follow-up was 33 months. Three patients developed a secondary myelodysplastic syndrome. The median
overall survival was 17.9 months; the projected overall survival at 1, 2 and 3 years was 66, 42 and 35%,
respectively. The median event-free survival was 11.8 months; the projected event-free survival at 1, 2 and
3 years was 50, 30 and 26%, respectively. Conclusion: The rituximab-EPOCH regimen is effective and
well tolerated, even in extensively pretreated patients with relapsed or refractory large B-cell lymphoma
and mantle-cell lymphoma
DOI: https://doi.org/10.1093/annonc/mdh093
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-154712
Journal Article
Published Version
Originally published at:
Jermann, M (2004). Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or trans-
formed B-cell lymphomas: results of a phase II study. Annals of Oncology, 15(3):511-516.
DOI: https://doi.org/10.1093/annonc/mdh093
Annals of Oncology 15: 511–516, 2004Original article DOI: 10.1093/annonc/mdh093
© 2004 European Society for Medical Oncology
Rituximab–EPOCH, an effective salvage therapy for relapsed, 
refractory or transformed B-cell lymphomas: results of a phase II 
study
M. Jermann1, L. M. Jost1, Ch. Taverna1, E. Jacky1, H. P. Honegger2, D. C. Betticher3, F. Egli4, 
Th. Kroner5 & R. A. Stahel1*
*Correspondence to: R. A. Stahel, Klinik und Poliklinik für Onkologie, 
University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland. 
Tel: +41-1-634-2871; Fax: +41-1-634-2872; E-mail: rolf.stahel@usz.ch
1University Hospital of Zurich, 2Triemli Hospital Zurich, 3Inselspital Bern, 4Kantonsspital Chur, 5Kantonsspital Winterthur, Switzerland
Received 12 August 2003; revised 9 October 2003; accepted 11 November 2003
Background: Relapsed or refractory diffuse large B-cell and mantle-cell lymphoma have a poor prognosis.
The EPOCH regimen and rituximab monotherapy have demonstrated activity as salvage therapies. Because of
their non-overlapping toxicity, we evaluated their combination as salvage therapy in a phase II study.
Patients and methods: Patients with relapsed or refractory CD20-positive large B-cell and mantle-cell
lymphoma were offered treatment with rituximab 375 mg/m2 intravenously (i.v.) on day 1, doxorubicin 15 mg/m2
as a continuous i.v. infusion on days 2–4, etoposide 65 mg/m2 as a continuous i.v. infusion on days 2–4, vincris-
tine 0.5 mg as a continuous i.v. infusion on days 2–4, cyclophosphamide 750 mg/m2 i.v. on day 5 and prednisone
60 mg/m2 orally on days 1–14.
Results: Fifty patients, with a median age of 56 years (range 23–72), entered the study. Twenty-five had pri-
mary diffuse large B-cell lymphoma, 18 transformed large B-cell lymphoma and seven mantle-cell lymphoma.
The median number of prior chemotherapy regimens was 1.7 (range one to four). The median number of treat-
ment cycles was four (range one to six). Possible treatment-related death occurred in two patients. Objective
responses were obtained in 68% of patients (28% complete responses, 40% partial responses). Nineteen patients
received consolidating high-dose chemotherapy with autologous stem-cell transplantation. The median follow-
up was 33 months. Three patients developed a secondary myelodysplastic syndrome. The median overall
survival was 17.9 months; the projected overall survival at 1, 2 and 3 years was 66, 42 and 35%, respectively.
The median event-free survival was 11.8 months; the projected event-free survival at 1, 2 and 3 years was 50, 30
and 26%, respectively.
Conclusion: The rituximab–EPOCH regimen is effective and well tolerated, even in extensively pretreated
patients with relapsed or refractory large B-cell lymphoma and mantle-cell lymphoma.
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Introduction
Relapsed or refractory diffuse large B-cell lymphoma and mantle-
cell lymphoma have a poor prognosis, with a long-term survival
<15% at 5 years when treated with conventional chemotherapy
[1]. High-dose chemotherapy improves the prognosis, but is not
feasible in a considerable number of patients due to either
advanced age, co-morbidities or lack of response to regimens used
for remission induction [2, 3]. The EPOCH regimen and rituximab
monotherapy have proven activity as salvage regimens, but they
rarely provide long-lasting remissions when used as a single
modality [4–6]. Since the majority of our patients had previously
been treated with CHOP (cyclophosphamide, doxorubicin, vincris-
tine and prednisone) chemotherapy, we chose the EPOCH regimen,
in which doxorubicin is administered as a continuous infusion
over 72 h, thereby reducing the risk of cardiotoxicity [7–10].
Furthermore, the experimental finding that MDR-1-mediated
resistance in tumor cells can be overcome by continuous exposure
at low drug concentrations rather than by a short exposure at
higher concentrations supports the continuous drug application
[11].
Because of the non-overlapping toxicity of rituximab and
chemotherapy, we evaluated the combination of rituximab and
EPOCH chemotherapy as salvage therapy for CD20-positive
large B-cell and mantle-cell lymphoma in a phase II study.
Patients and methods
Patient selection
Eligible patients had to have histologically confirmed relapsed or refractory
diffuse large B-cell or mantle-cell lymphoma with positive CD20 immuno-
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histochemistry, an Eastern Cooperative Oncology Group (ECOG) perform-
ance status (PS) of 0–2, age 16–75 years, adequate bone marrow,  hepatic and
renal function, a life expectancy of >3 months, and a normal cardiac ejection
fraction. Exclusion criteria were: a cumulative dose of doxorubicin received
>400 mg/m2, a history of gastrointestinal bleeding, gastroduodenal ulcers,
uncontrolled infections, HIV infection, viral hepatitis, immunosuppression,
previous chemotherapy for other tumors, pregnancy or breast feeding. Written
informed consent was required. The study was carried out with ethics committee
approval.
Treatment plan
Patients received rituximab 375 mg/m2 intravenously (i.v.) on day 1, doxo-
rubicin 15 mg/m2 as a continuous i.v. infusion on days 2–4, etoposide 65 mg/m2
as a continuous i.v. infusion on days 2–4, vincristine 0.5 mg as a continuous
i.v. infusion on days 2–4, cyclophosphamide 750 mg/m2 i.v. on day 5 and
prednisone 60 mg/m2 orally on days 1–14. The infusional part of the EPOCH
regimen was shortened by 1 day while maintaining the original cumulative
dose of etoposide, vincristine and doxorubicin [4] in order to allow for a
5-day in-patient stay. The rituximab–EPOCH regimen was given for four to
six cycles every 21 days. Patients with normal echocardiography after four
cycles and <300 mg/m2 of doxorubicin prior to study entry were allowed to
receive up to six cycles of rituximab–EPOCH if they were not candidates for
high-dose chemotherapy. Patients <60 years old who had not received high-
dose chemotherapy prior to study entry were offered to undergo stem-cell
collection and high-dose chemotherapy with autologous stem-cell transplant-
ation if at least a partial response was achieved after three cycles of rituximab–
EPOCH salvage therapy. In those patients the fourth cycle was used for stem-
cell mobilization. Safety evaluation consisting of a physical examination and
full blood cell counts were performed weekly; routine chemical values were
measured prior to each cycle.
Criteria for response and toxicity evaluation
Computer tomography scans were required within 3 weeks of registration and
assessment was repeated after cycle 2 and 4, at the end of treatment, and every
3 months until disease progression. Response was evaluated by bidimensional
measurements of lesions according to WHO criteria. After progression,
patients were followed to determine overall survival. ECOG criteria were used
to define PS. Toxicity was evaluated according to the National Cancer Institute
(NCI) criteria [12].
Statistical analysis
Event-free survival was calculated from the date of study entry to the last
control, progression or relapse, or death due to any reason. Overall survival
was measured from study entry to the date of the last control or death.
Projected survival was calculated using the Kaplan–Meier method.
Results
Patient characteristics
In this phase II study, 50 patients were enrolled at five centers in
Switzerland between July 1998 and February 2001. Table 1 shows
the characteristics of the 50 patients. Forty-seven of 50 patients
had previously been treated with anthracyclines: 43 with CHOP or
a variation of CHOP, and four with VACOP-B chemotherapy.
The median dose of prior doxorubicin in these patients was
300 mg/m2 (range 50–400).
Response and survival data
A total of 181 chemotherapy cycles of rituximab–EPOCH were
given to the 50 patients (median four, range one to six). Response
evaluation was possible in 47 patients. Fourteen patients (28%)
achieved a complete remission and 20 patients (40%) a partial
remission, thus an objective response was obtained in 68% of
patients. The median follow-up time was 33 months. The median
event-free survival was 11.8 months and the median overall
survival was 17.9 months (Figure 1). Event-free survival was
more favorable among patients with a low or low-intermediate
Table 1. Patient characteristics
aInitial histology was follicular lymphoma in 14 and composite 
lymphoma in four patients.
bAt the time of study entry.
Characteristic n
Number of patients 50
Males/females 30/20
Age (years) [median (range)] 56 (32–72)
Histological findings
Diffuse large B-cell lymphoma 25
Transformed B-cell lymphomaa 18
Mantle-cell lymphoma 7
Stage
II 6
III 10
IV 34
International Prognostic Indexb
Low 8
Low/intermediate 13
High/intermediate 18
High 11
B-symptoms 20
Elevated lactate dehydrogenase 36
Median (range) time from diagnosis to study
 participation (months)
14 (2–173)
Response to the first-line chemotherapy
Complete remission 17
Partial remission 19
Stable disease 5
Progressive disease 9
Previous treatment
Radiotherapy 19
Average No. (range) prior chemotherapy lines 1.7 (1–4)
1 regimen 26
≥2 regimens 24
Rituximab 8
High-dose chemotherapy 5
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International Prognostic Index (IPI) compared with the inter-
mediate-high or high group (P = 0.0017) (Figure 2). Event-free
survival according to histology showed only minor differences.
The median event-free survival was 15 months in mantle-cell
lymphoma patients (n = 7), 12.4 months in transformed B-cell
lymphoma patients (n = 18) and 9.7 months in diffuse large B-cell
lymphoma patients (n = 25). The 14 patients who did not respond
to first-line chemotherapy (five stable disease, nine progressive
disease) also had a worse prognosis after the rituximab–EPOCH
chemotherapy. The median event-free survival for those patients
was 4 versus 15 months for the responders and the median overall
survival was 8 and 29 months, respectively (P <0.001) (Figure 3).
Nineteen out of 31 patients <60 years old without prior high-
dose chemotherapy achieved a sufficient response to rituximab–
EPOCH chemotherapy and underwent high-dose chemotherapy
with autologous stem-cell support (61.3%). As might be expected,
patients able to undergo high-dose chemotherapy had a better
event-free survival as compared with the others (median event-
free survival not reached versus 9.9 months; 2-year event-free
survival 53% versus 16%, P = 0.0025) (Figure 4).
Toxicity
Infusion-related reactions (fever, chills, bronchospasm) occurred
in 14 of 50 patients (28%), mainly during the first infusion of
rituximab. Despite this, a dose reduction of rituximab was not
necessary. Febrile neutropenia leading to hospitalization occurred
in 13 of 181 cycles (7%). In eight patients a bacterial infection
could be identified. One patient had a herpes zoster infection.
Grade 3 or 4 anemia was observed in 15 of 181 cycles, and grade 3
or 4 thrombocytopenia in two of 151 cycles.
Two patients died a sudden death. A 66-year-old woman with
stage IVA disease died of an unknown cause at home after the first
chemotherapy cycle. A 70-year-old woman with stage IVB
disease died 8 days after the fourth chemotherapy cycle after the
onset of diarrhea. An autopsy was performed in the latter patient,
Figure 1. Event-free (solid line) and overall (dashed line) survival among 
50 patients assigned to chemotherapy with rituximab–EPOCH.
Figure 2. Event-free survival among 50 patients after therapy with 
rituximab–EPOCH according to the International Prognostic Index. 
Twenty-one patients with low (eight patients) or low-intermediate 
(13 patients) risk (solid line) versus 29 patients with high-intermediate 
(11 patients) or high (18 patients) risk (dashed line) (log-rank test 
P = 0.0017).
Figure 3. Event-free survival among 50 patients after therapy with 
rituximab–EPOCH according to the response to the first-line 
chemotherapy: 36 responders (dashed line) and 14 non-responders (solid 
line) (log-rank test P = 0.0017).
Figure 4. Event-free survival among 19 patients with (dashed line) and 31 
patients without (solid line) autologous stem-cell transplantation after 
therapy with rituximab–EPOCH (log-rank test P = 0.0025).
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but no obvious reason for death was discovered. A probably
independent cerebral hemorrhage occurred in a 44-year-old man
with stage IVB disease after the first chemotherapy cycle. The
platelet count was normal at the time of hemorrhage. The main
toxicities are listed in Table 2.
Two patients had signs of a secondary myelodysplastic syndrome
at study entry, as judged by dysmorphorphic changes in all three
lineages, and one patient after three cycles of treatment. Two
patients had received two lines and one had received four lines of
previous chemotherapy. All patients responded to the treatment,
but two died of consequences of bone marrow failure and second-
ary leukemia, 10 and 14 months after study entry, and one of
progressive disease.
Discussion
The EPOCH regimen for relapsed non-Hodgkin’s lymphoma was
based on the rationale that the continuous i.v. application of etopo-
side, vincristine and doxorubicin might be of advantage to over-
come multidrug resistance associated with the overexpression of
MDR-1 and its product p-glycoprotein [11]. The first report of
results of an EPOCH study was based on 74 patients treated at the
NCI for relapsed or refractory lymphoma after conventional i.v.
therapy [6]. The overall response rate was 87%, with complete
responses mostly restricted to the subgroup of patients with prior
complete responses. The 1-year event-free survival was 28%. The
regimen was well tolerated, with the major toxicity being hemato-
logical, with a 17% incidence of febrile neutropenia. An 8-year
follow-up of 131 patients by Gutierrez et al. [5] demonstrated a
response rate of 74%, a 3-year event-free survival of 15% and a
3-year overall survival of 41%. Again, hospitalization for neutro-
penia occurred in 18% of cycles. A multicenter study from the
Baylor–Charles A. Sammons Cancer Center involving 93 patients
reported a response rate of 57%, with a 3-year event-free survival
of 7% and a 3-year overall survival of 19% [13]. The activity of
the EPOCH regimen has since been confirmed by several other
smaller studies [14, 15]. The cisplatin-based ESHAP regimen is
another widely used regimen for refractory or relapsed lymph-
oma. The results reported are similar; however, its toxicity profile
with regard to renal and hematological side effects is much less
favorable than that of the EPOCH regimen [16], which might have
the potential to preclude some patients from subsequent high-dose
chemotherapy and is associated with a poorer quality of life.
Rituximab has single-agent activity in refractory and relapsed
B-cell lymphoma. The first report from Coiffier et al. [4] on 55
patients demonstrated an overall response rate of 31%, including
37 and 33%, respectively, for large B-cell and mantle-cell lymph-
oma. Duration of response exceeded 3 months. These results
have recently been confirmed in patients with large B-cell and
mantle-cell lymphoma relapsing after high-dose chemotherapy
and autologous stem-cell transplantation [17]. The median time to
relapse was 10 months in that study.
Our phase II trial evaluated the safety and efficacy of rituximab
in combination with EPOCH chemotherapy in patients with
relapsed or refractory diffuse large-cell or mantle-cell lymphoma.
The rituximab–EPOCH regimen was found to be effective and
well tolerated, even in extensively pretreated patients. A response
rate of 68% was achieved. With a median follow-up of 33 months,
median overall survival was 17.9 months and median event-free
survival was 11.8 months. The projected 3-year event-free sur-
vival was 26%, and the projected 3-year overall survival was 35%.
The regimen was well tolerated, the major toxicity being hemato-
logical, leading to hospitalization for fever and neutropenia in 7%
of the treatment cycles. Two patients died a sudden death and
three patients developed a secondary myelodysplastic syndrome.
The feasibility of combining rituximab with EPOCH has also
been reported by another group [18]. In their study, 24 patients
with untreated and 15 patients with relapsed or refractory lymph-
omas of different histologies were treated. In contrast to our study,
hospitalization for febrile neutropenia occurred in 20% of treat-
ment cycles.
How do our results compare with EPOCH alone? In the absence
of randomized studies we had to compare our results with those
from the two large published studies mentioned above [5, 13].
There does not appear to be a difference in the overall response
rates or complete response rates. The overall response rate in our
study is within the range of 57 to 74%, as published in studies
with EPOCH alone. The median event-free survival in our study
was 12 months, compared with 7 and 4 months in the studies with
EPOCH alone [5, 13]. The median 3-year event-free survival in
our study was 26%, compared with 15 and 7% in the studies with
EPOCH alone [5, 13]. Thus rituximab–EPOCH chemotherapy
appears to offer a benefit over EPOCH alone in relapsed or refrac-
tory large B-cell and mantle-cell lymphoma. It is unlikely that the
benefit could be entirely explained by the fact that 38% of patients
Table 2. Adverse events
Adverse event n
Infusion-related reactions [n (%)] 14/50 (28)
Unplanned hospitalizations [n (%)] 13/18 (17)
Bacterial infections/herpes zoster 8/1
Neutrophil toxicity WHO grade (out of 181 cycles)
II 4
III 6
IV 28
Platelet toxicity WHO grade (out of 181 cycles)
II 5
III 1
IV 1
Hemoglobin toxicity WHO grade (out of 181 cycles)
II 19
III 14
IV 1
Neurotoxicity WHO grade II 7
Secondary myelodysplastic syndrome 3
Possible treatment-related death 2
Probable treatment-independent death 1
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in our study underwent subsequent high-dose chemotherapy and
autologous stem-cell transplantation. High-dose chemotherapy
with autologous hematopoietic stem-cell transplantation does
improve the outcome in patients with relapsed or refractory
aggressive non-Hodgkin’s lymphoma [2], but only to a small
degree, and a considerable number of patients in the two studies
using EPOCH chemotherapy alone also received treatment
intensification. One fact that has to be considered, however, is the
eligibility bias in our study for patients with CD20 expression.
A major difficulty in comparing overall survival data regards
the inclusion of ∼25% of patients with low-grade lymphoma in
the two reports of EPOCH chemotherapy alone [5, 6]. However,
neither of these could identify histology as a prognostic factor for
survival. Poor prognostic factors identified in our study were lack
of response to first-line chemotherapy and high-intermediate/high
IPI. Achieving a response to first-line chemotherapy appears to be
a good prognostic factor [1, 19].
While it is obvious that patients <60 years of age eligible for
subsequent high-dose chemotherapy with autologous stem-cell
transplantation have a better outcome than the remainder of the
patients, it remains of note that a long-term benefit with rituxi-
mab–EPOCH was also seen in the absence of high-dose consoli-
dation. The 2-year event-free survival in this subgroup of patients
was 16%.
Our study was restricted to patients who had received a cumulat-
ive dose of doxorubicin of ≤ 300 mg/m2. This might have been an
overly cautious selection of patients, since infusional doxorubicin
is associated with a low cardiac toxicity [5]. Given the potential
benefit of the treatment strategy used in our study, patients
who have received larger cumulative doses of doxorubicin might
also be considered for rituximab and EPOCH under appropriate
cardiac monitoring
Based on Coiffier et al.’s [20] initial report of the combination
of rituximab and CHOP and the prospectively randomized study
of CHOP with or without rituximab as first-line therapy for large
B-cell lymphoma in patients aged 60–80 years, there is currently
an increasing trend towards using rituximab in first-line chemo-
therapy for aggressive non-Hodgkin’s lymphoma [21, 22]. How-
ever, this is unlikely to influence the use of rituximab in
combination for patients with relapsed or refractory disease. In
follicular lymphoma, retreatment with rituximab has proven to be
save and effective [23].
Our study demonstrated the combination of rituximab–EPOCH
chemotherapy to be well tolerated and effective for patients with
relapsed and refractory large B-cell and mantle-cell lymphoma. It
suggests this regimen to be superior in event-free survival com-
pared with EPOCH chemotherapy alone, with the potential bias
that the regimen is only applicable to CD20-positive tumors. The
high activity of this regimen suggests that drug resistance in
aggressive lymphoma might not be drug specific per se, but could
be due to an increase of the apoptotic threshold of tumor cells,
which could, at least in part, be overcome by pretreatment with
rituximab.
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